Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis

Rheumatology International

Volumn 32, Issue 4, 2012, Pages 963-969

  Inotai, András ^a   Rojkovich, Bernadette ^b   Fülöp, Angéla ^b   Jászay, Emese ^b   Ágh, Tamás ^a   Mészáros, Ágnes ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Polyclinic of the Hospitaller Brothers of St John of God ^*  (Hungary)

Author keywords

Biological therapies; Disease specific quality of life; Health related quality of life; Rheumatoid arthritis; Time trade off; Utility

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL ASSESSMENT TOOL; CORRELATION COEFFICIENT; COST UTILITY ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS QUALITY OF LIFE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; HUNGARY; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84863532364     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1721-x     Document Type: Article

References (37)

1. Kaló Z, Péntek M (2005) Az életmin}oség mérése. In: Gulácsi L (ed) Egészsé ggazdaságtan, 1st edn edn. Medicina Könyvkiadó Rt, Budapest, pp 161-189
2. Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW (2003) Health care, cost, quality and outcomes-Ispor book of terms. ISPOR, USA
3. Currey SS, Rao JK, Winfield JB, Callahan LF (2003) Performance of a generic health-related quality of life measure in a clinic population with rheumatic disease. Arthritis Rheum 49:658-664 (Pubitemid 37296471)
4. The EuroQoL Group (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16:199-208. doi:10.1016/0168- 8510(90)90421-9
5. de Jong Z, van der Heijde D, McKenna SP, Whalley D (1997) The reliability and validity of the RAQoL: a rheumatoid arthritisspecific quality of life instrument. Br J Rheumatol 36:878-883
6. Haroon N, Aggarwal A, Lawrence A, Agarwal V, Misra R (2007) Impact of rheumatoid arthritis on quality of life. Mod Rheumatol 17:290-295. doi:10.1007/s10165-007-0604-9 (Pubitemid 47263819)
7. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 60:1571-1582. doi: 10.1016/j.socscimed.2004.08.034 (Pubitemid 40126441)
8. Bingham CO (2008) Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis 66:210-215
9. Gaffo A, Saag KG, Curtis JR (2006) Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63:2451-2465. doi:10.2146/ ajhp050514 (Pubitemid 46391141)
10. Brodszky V, Kárpáti K, Gulácsi L, Péntek M, Orlewska E (2008) A rituximab kezelés kö ltség- hasznosságának modellezése rheumatoid arthritisben TNF-alfa gátló kezelés után Magyarországon. IME 8:41-46
11. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:iii-iv, xi-xiii, 1-229
12. Kobelt G (2007) Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 66(Suppl 3):iii35-iii39. doi:10.1136/ ard.2007.078964 (Pubitemid 350032630)
13. Rashidi AA, Anis AH, Marra CA (2006) Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with health utilities index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes 4:25. doi:10.1186/1477- 7525-4-25
14. Kobelt G, Eberhardt K, Jönsson L, Jönsson B (1999) Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 42:347-356. doi:10.1002/1529-0131 (199902)42:2\347:AID-ANR18[3.0.CO;2-P (Pubitemid 29072853)
15. Neumann PJ, Goldie SJ, Weinstein MC (2000) Preference-based measures in economic evaluation in health care. Annu Rev Public Health 21:587-611. doi:10.1146/annurev.publhealth.21.1.587 (Pubitemid 30480336)
16. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, Clarke AE, Gignac MA, Anis AH (2007) Not all "qualityadjusted life years" are equal. J Clin Epidemiol 60:616-624. doi: 10.1016/j.jclinepi.2006.09.006 (Pubitemid 46711077)
17. Dolan P (2001) Output measures and valuation in health. In: Drummond M, McGuire A (eds) Economic evaluation in health care merging theory with practice. Oxford University Press, New York, pp 46-67
18. Drummond MF, Schulper MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, New York
19. Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40:593-600 (Pubitemid 17084806)
20. Tijhuis GJ, Jansen SJ, Stiggelbout AM, Zwinderman AH, Hazes JM, Vlieland TP (2000) Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 59:892-897. doi:10.1136/ard.59.11.892
21. Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5:1-30 (Pubitemid 16098443)
22. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324 (Pubitemid 18091653)
23. Hungarian Ministry of Health (2008) Biological therapies in rheumatic diseases - Protocol of the Ministry of Health. http://www.eum.hu/ egeszsegpolitika/minosegfejlesztes/ reumatologia. Accessed 22 Oct 2009
24. Lillegraven S, Kvien TK (2007) Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:827-840. doi:10.1016/j.berh.2007.05.004 (Pubitemid 47377806)
25. Rojkovich B, Lovas K, Tatárné EH, Szabó CS, Korányi A (2002) Rheumatoid arthritis életmin}oség skála (RAQoL) hazai valida ́lása. Komplex fizioterápia és oktatás hatása a rheumatoid arthritises betegek életmin}oségére. Magy Reumatol 43:136
26. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36:551-559. doi:10.1093/rheumatology/36.5.551
27. Brodszky V, Bálint P, Géher P, Hodinka L, Horváth G, Koó E ́ , Péntek M, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L (2009) Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 30:199-205. doi:10.1007/s00296-009-0936-1
28. Whalley D, McKenna SP, de Jong Z, van der Heijde D (1997) Quality of life in rheumatoid arthritis. Br J Rheumatol 36:884-888
29. Ariza-Ariza R, Hernandez-Cruz B, Carmona L et al (2006) Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum 55:751-756. doi:10.1002/art.22226 (Pubitemid 44619189)
30. Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond T, Brazier J (2007) Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Care Res 57:963-971. doi:10.1002/ art.22885 (Pubitemid 47237321)
31. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095-1108 (Pubitemid 127453463)
32. Péntek M, Szekanecz Z, Czirják L, Gy Poór et al (2008) Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary [A betegségprogresszió hatása az egészségi állapotra, életmin} oségre és költségekre rheumatoid arthritisben Magyarországon]. Orv Hetil 149:733-741. doi: 10.1556/OH.2008.28294 (Pubitemid 351637813)
33. Péntek M, Kobelt G, Czirják L, Szekanecz Z, Rojkovich B, Polgár A, Genti G, Kiss CG, Brodszky V, Májer I, Gulácsi L (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437-1439 (Pubitemid 46898132)
34. Witney AG, Treharne GJ, Tavakoli M, Lyons AC, Vincent K, Scott DL, Kitas GD (2006) The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology 45:975-981. doi:10.1093/rheumatology/kel027 (Pubitemid 44283052)
35. Scott DL, Khoshaba B, Choy EH, Kingsley GH (2007) Limited correlation between the Health assessment questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ. Ann Rheum Dis 66:1534-1537. doi:10.1136/ard.2007.073726 (Pubitemid 350032666)
36. Marra CA, Esdaile JM, Guh D et al (2004) A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 42:1125-1131 (Pubitemid 39472119)
37. Bejia I, Salem KB, Touzi M, Bergaoui N (2006) Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients. Clin Rheumatol 25:38-41. doi:10.1007/s10067- 005-1125-6